Spero Therapeutics (SPRO) Q2 2024 earnings summary

Executive summary

• Provided business and clinical pipeline updates, including the departure of Chief Medical Officer Kamal Hamed and interim oversight by board member Dr. John C. Pottage, Jr.

• Highlighted progress in clinical-stage assets: SPR720, Tebipenem HBr, and SPR206, with SPR720 and tebipenem HBr advancing in key trials.

• Net loss for Q2 2024 was $17.9 million, up from $11.9 million in Q2 2023; six-month net loss was $30.5 million, up from $25.2 million year-over-year.

• Cash and cash equivalents were $63.5 million as of June 30, 2024, expected to fund operations into late 2025.

• No product sales to date; revenue derived from government contracts and collaboration agreements, notably with GSK and Pfizer.

Financial highlights

• Total revenue for Q2 2024 was $10.2 million, up from $2.7 million in Q2 2023, driven by increased collaboration and grant revenue.

• Research and development expenses rose to $23.7 million in Q2 2024 from $9.5 million in Q2 2023, mainly due to higher costs for Tebipenem HBr and SPR720 trials.

• General and administrative expenses decreased to $5.5 million in Q2 2024 from $6.1 million in Q2 2023.

• Interest income for Q2 2024 was $1.2 million, including $0.4 million from a significant financing component under the GSK License Agreement.

• Cash used in operations for the first half of 2024 was $12.8 million, a decrease from $31.4 million in the prior year period.

Outlook and guidance

• Cash and non-dilutive funding expected to fund operations into late 2025, with additional capital needed thereafter.

• Anticipates three remaining milestone payments from GSK, each approximately $24 million, every six months.

• Expects to complete enrollment for the Tebipenem HBr phase 3 trial in the second half of 2025.

• Plans to share comprehensive SPR720 clinical data, including phase 2a and phase 1 studies, in Q4 2024.

• If additional capital is not secured, spending reductions and program delays may occur.